GHRP-2 5mg

Overview

Growth Hormone–Releasing Peptide-2 (GHRP-2), also known as pralmorelin, is a synthetic six–amino acid peptide used exclusively in laboratory research to study signaling mediated by the growth hormone secretagogue receptor (GHSR-1a). As one of the earliest synthetic ligands developed for this receptor class, GHRP-2 is frequently cited in foundational research examining ghrelin-associated receptor biology and neuroendocrine signaling behavior.

In controlled experimental environments, GHRP-2 is applied as a receptor-selective agonist to evaluate GHSR-1a activation, downstream intracellular signaling, and tissue-specific receptor responses. All data associated with this compound originate from in-vitro assays or animal research models and are interpreted solely within a non-clinical research context.

Biochemical Characteristics

GHRP-2 is a hexapeptide incorporating multiple D-amino acid residues, a design feature commonly used in peptide research to enhance conformational stability and reduce enzymatic degradation during experimental use. This structural configuration supports high-affinity interaction with the growth hormone secretagogue receptor, making GHRP-2 a valuable probe for receptor-binding and signal-initiation studies.

Within biochemical and cell-based assays, GHRP-2 is routinely used to measure ligand–receptor binding parameters, second-messenger signaling responses, and transcription-linked readouts associated with ghrelin receptor activation. Early research involving growth hormone–releasing peptides helped define this class of molecules as tools for dissecting neuroendocrine communication pathways in experimental systems.

Research Applications

GHRP-2 is utilized in laboratory research across a range of mechanistic study designs, including:

• Receptor pharmacology: assessment of GHSR-1a activation profiles, ligand selectivity, and intracellular signaling kinetics in cell models
• Skeletal muscle biology: evaluation of protein synthesis and degradation pathways, including markers associated with ubiquitin–proteasome regulation, in cellular and animal systems
• Energy balance and feeding regulation: investigation of ghrelin receptor involvement in hypothalamic and peripheral circuits governing nutrient sensing in preclinical models
  
• 
  Cardiac stress biology: analysis of apoptosis-related markers and oxidative stress pathways in cardiomyocyte cultures and myocardial injury models
• Immunological research: examination of ghrelin-linked signaling influences on thymic activity and T-cell development in animal studies
• Neuroscience: exploration of sleep-wake regulation, nociceptive signaling, and receptor interaction networks in rodent experimental paradigms
  

All applications are confined to non-clinical laboratory research.

Pathway / Mechanistic Context

GHRP-2 activates GHSR-1a, a G protein–coupled receptor involved in neuroendocrine signaling and metabolic sensing. Experimental receptor engagement initiates intracellular cascades involving G protein signaling, kinase activation, and transcription-related regulatory events associated with growth modulation, stress adaptation, and metabolic coordination.

Beyond classical pituitary signaling, preclinical studies have used GHRP-2 to explore GHSR-1a expression and function in peripheral tissues and central nervous system regions. Reported findings in experimental models describe receptor-mediated influences on skeletal muscle protein turnover, cardiomyocyte survival pathways, thymic cellular output, sleep architecture modulation, and supraspinal pain-processing circuits.

The identification and characterization of the growth hormone secretagogue receptor established a framework for using synthetic agonists such as GHRP-2 to map ghrelin-related GPCR signaling behavior in controlled research systems.

Preclinical Research Summary

Muscle Protein Turnover Models

Animal studies, including large-animal and agricultural research models, have examined GHRP-2 in the context of skeletal muscle growth regulation. Reported observations include altered expression of ubiquitin-ligase markers (e.g., atrogin-1, MuRF1) and shifts in anabolic versus catabolic signaling under experimentally defined growth conditions.

Feeding Behavior and Metabolic Signaling

Rodent studies have demonstrated that ghrelin receptor activation influences hypothalamic pathways involved in appetite regulation and energy balance. Experimental endpoints include food-intake metrics, hormonal signaling markers, and behavioral outputs linked to receptor engagement.

Cardiac Cellular Stress Models

Cell-based and in-vivo myocardial stress studies have used GHRP-2 to evaluate signaling associated with apoptosis and oxidative stress, contributing to broader investigations of ghrelin receptor involvement in cardiac cellular responses.

Thymic Function and Immune Development

Preclinical immunology research has explored ghrelin-associated signaling effects on thymic structure and T-cell maturation, particularly in models of aging or physiological stress.

Sleep Architecture and Neuroendocrine Rhythms

Experimental sleep studies have applied ghrelin receptor agonists to analyze changes in sleep-stage distribution and neuroendocrine rhythmicity using electrophysiological and behavioral endpoints.

Nociception and Receptor Crosstalk

Murine models have investigated interactions between ghrelin receptor activation and supraspinal opioid signaling systems, supporting studies of receptor specificity and pathway overlap in pain-processing research.

Form & Analytical Testing

GHRP-2 is supplied as a research-grade peptide reagent intended for laboratory use. Molecular identity and purity are commonly confirmed using analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS). Handling, storage, and experimental use should follow institutional laboratory protocols and applicable regulations governing research-only materials.

RUO Disclaimer

The products offered on this website are provided for in-vitro research purposes only. In-vitro studies (Latin: in glass) are conducted outside of a living organism. These materials are not drugs or medicines and have not been approved by the FDA to diagnose, prevent, treat, or cure any disease or medical condition. Administration to humans or animals is strictly prohibited by law.

All products are prepared using a lyophilization (freeze-drying) process, a preservation method designed to maintain peptide integrity and stability during transport. In lyophilized form, products remain chemically stable for shipment for approximately three to four months under appropriate conditions.

After reconstitution with bacteriostatic water, peptides should be stored under refrigerated conditions to preserve stability. Once rehydrated, peptide solutions typically maintain stability for up to 30 days when kept cold.

Lyophilization—also referred to as cryodesiccation—is a controlled dehydration technique in which the peptide solution is frozen and exposed to reduced pressure. This environment causes ice to transition directly from solid to vapor through sublimation, removing moisture without disrupting molecular structure. The result is a dry, porous, white solid commonly referred to as a lyophilized peptide, which may be stored at room temperature until reconstitution is required.

Upon receipt, peptides should be protected from heat and light exposure. For short-term use—ranging from several days to weeks or a few months—storage under refrigeration at temperatures below 4°C (39°F) is generally acceptable. Lyophilized peptides may also remain stable at ambient temperatures for limited durations, making room-temperature storage suitable when use is anticipated within weeks or months.

For long-term preservation, particularly when storage is expected to extend over several months or years, freezer storage is recommended. Maintaining peptides at −80°C (−112°F) provides optimal conditions for preserving molecular stability and integrity over extended periods.